- Home
- INBX vs PRCT Comparison
INBX vs PRCT Comparison
Compare INBX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | PRCT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBX | PRCT |
|---|---|---|
| Price | $93.58 | $20.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $150.00 | $35.44 |
| AVG Volume (30 Days) | 331.5K | ★ 1.9M |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | $1,300,000.00 | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | 37.22 |
| 52 Week Low | $20.55 | $19.35 |
| 52 Week High | $155.29 | $62.17 |
Technical Indicators
Market Signals| Indicator | INBX | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 40.52 |
| Support Level | $85.94 | $19.64 |
| Resistance Level | $96.12 | $29.27 |
| Average True Range (ATR) | 7.44 | 1.47 |
| MACD | 0.78 | -0.09 |
| Stochastic Oscillator | 33.00 | 27.71 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.